- Home
- PBYI vs EOD Comparison
PBYI vs EOD Comparison
Compare PBYI & EOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PBYI | EOD |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.4M | 265.3M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | PBYI | EOD |
|---|---|---|
| Price | $5.88 | $5.97 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 467.8K | 104.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.28% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $27,685,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.84 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.58 | $4.24 |
| 52 Week High | $7.68 | $6.27 |
Technical Indicators
Market Signals| Indicator | PBYI | EOD |
|---|---|---|
| Relative Strength Index (RSI) | 40.44 | 38.46 |
| Support Level | $5.57 | $5.92 |
| Resistance Level | $7.25 | $6.01 |
| Average True Range (ATR) | 0.43 | 0.07 |
| MACD | -0.11 | -0.02 |
| Stochastic Oscillator | 17.89 | 11.63 |
Price Performance
Historical ComparisonAbout PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
About EOD Allspring Global Dividend Opportunity Fund of Beneficial Interest
Allspring Global Dividend Opportunity Fund is a diversified closed-end management investment company. Its primary investment objective is to seek a high level of current income. The fund's secondary objective is the long-term growth of capital. The fund allocates its assets between two separate investment strategies or sleeves. Under normal market conditions, the fund allocates approximately 80% of its total assets to an equity sleeve comprised of common stocks.